Ferrier C, Esler M D, Eisenhofer G, Wallin B G, Horne M, Cox H S, Lambert G, Jennings G L
Alfred and Baker Medical Unit, Alfred Hospital, Melbourne, Australia.
Hypertension. 1992 Jan;19(1):62-9. doi: 10.1161/01.hyp.19.1.62.
In essential hypertension sympathetic nerve firing is commonly increased. A central nervous system origin has been presumed but not tested directly. To estimate cerebral norepinephrine release in essential hypertension, spillover of norepinephrine into the cerebrovascular circulation was measured by isotope dilution, with high internal jugular venous sampling. Norepinephrine was released into the cerebrovascular circulation in both hypertensive patients and healthy volunteers and was present after administration of the ganglion blocker trimethaphan and in patients with sympathetic nervous failure, indicating that brain neurons and not cerebrovascular sympathetic nerves were the probable source. Although differing among hypertensive patients, norepinephrine spillover on average was higher in the hypertensive patients (153 +/- 41 pmol/min) than in healthy subjects (59 +/- 12 pmol/min; p less than 0.05), and was elevated in six of 17 patients, in whom the accompanying whole body norepinephrine spillover rate was higher than in the remaining 11 patients (p less than 0.01). To test for a possible link between brain norepinephrine release and human sympathetic nervous function, the effect of the tricyclic antidepressant desipramine (0.3 mg/kg i.v.) on both brain and whole body norepinephrine spillover was measured in healthy volunteers. Desipramine lowered the cerebrovascular spillover of norepinephrine, its precursor dihydroxyphenylalanine, and its metabolite dihydroxyphenylglycol by 50-80% and produced a mean fall of 35% in whole body norepinephrine spillover. One interpretation of these results is that human sympathetic nerve firing is dependent on norepinephrine release within the brain and that increased cerebral norepinephrine release may possibly be present in some patients with essential hypertension, underlying their higher sympathetic nerve firing rates.
在原发性高血压中,交感神经放电通常会增加。虽然推测交感神经放电增加源于中枢神经系统,但尚未得到直接验证。为了评估原发性高血压患者脑内去甲肾上腺素的释放情况,采用同位素稀释法并通过高位颈内静脉采样,测量去甲肾上腺素向脑血管循环中的溢出量。无论是高血压患者还是健康志愿者,去甲肾上腺素均会释放到脑血管循环中,且在给予神经节阻滞剂三甲硫吩后以及交感神经功能衰竭的患者体内也存在,这表明脑神经元而非脑血管交感神经可能是其来源。尽管高血压患者之间存在差异,但高血压患者去甲肾上腺素的平均溢出量(153±41 pmol/分钟)高于健康受试者(59±12 pmol/分钟;p<0.05),并且17例患者中有6例的去甲肾上腺素溢出量升高,这些患者伴随的全身去甲肾上腺素溢出率高于其余11例患者(p<0.01)。为了测试脑内去甲肾上腺素释放与人体交感神经功能之间可能存在的联系,在健康志愿者中测量了三环类抗抑郁药地昔帕明(0.3 mg/kg静脉注射)对脑和全身去甲肾上腺素溢出量的影响。地昔帕明使去甲肾上腺素、其前体二羟基苯丙氨酸及其代谢产物二羟基苯乙二醇的脑血管溢出量降低了50 - 80%,并使全身去甲肾上腺素溢出量平均下降了35%。这些结果的一种解释是,人体交感神经放电依赖于脑内去甲肾上腺素的释放,并且在一些原发性高血压患者中可能存在脑内去甲肾上腺素释放增加的情况,这是其较高交感神经放电率的潜在原因。